Patents Assigned to Merck
  • Solutions and processes for removal of sidewall residue after dry etching
    Patent number: 6605230
    Abstract: The present invention relates to a novel process for removing sidewall residue after dry-etching process. Conventionally, after dry-etching, photoresist and sidewall residues are removed by ozone ashing and hot sulfuric acid. Normally, they are hard to be removed completely. It was found in the present invention that the addition of fluorine-containing compound, preferably hydrogen fluoride and ammonium fluoride, in sulfuric acid results in complete removal of photoresist and sidewall residue without the need for stripper. The process is simple and does not affect the original procedures or the other films on the substrate. The present invention also relates to a novel solution for removing sidewall residue after dry-etching, which comprises sulfuric acid and a fluorine-containing compound, preferably hydrogen fluoride and ammonium fluoride, in the range of from 10:1 to 1000:1 by weight.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: August 12, 2003
    Assignee: Merck Patent GmbH
    Inventors: Ming-Chi Liaw, Tien-Sheng Chao, Tan-Fu Lei
  • Protein tyrosine phosphate-1B (PTP-1B) deficient mice and uses thereof
    Patent number: 6605753
    Abstract: The present invention provides mice that have had their PTP-1B genes disrupted by targeted homologous recombination. The mice have no detectable PTP-1B protein, yet appear to be physiologically normal. However, in the fed state on a normal diet, the mice have half the level of circulating insulin as their wild-type littermates. In glucose and insulin tolerance tests, the mice show an increased insulin sensitivity. When fed a high fat, high carbohydrate diet, the mice show a resistance to weight gain as compared to their wild-type littermates. Methods making the mice and cell lines derived from the mice are also provided. The present invention also provides methods of identifying inhibitors of the enzymatic activity of PTP-1B as well as inhibitors identified by such methods.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: August 12, 2003
    Assignees: Merck & Co., Inc., McGill University
    Inventors: Brian Kennedy, Paul Payette, Michael Gresser, Chidambaram Ramachandran, Michel Tremblay, Mounib Elchebly
  • Cosmetic body pigment and process for preparing the same
    Publication number: 20030147819
    Abstract: A cosmetic body pigment having a good skin feel, no blue color, a high soft focusing effect (low viewing angle dependency of reflected light intensity), a natural color tone against the skin, and a moderate hiding power (wrinkle hiding effect) is provided. The cosmetic body pigment is characterized in that TiO2 fine particles are deposited separately with form of mono layer on the surface of a thin-platelet like substrate.
    Type: Application
    Filed: January 22, 2003
    Publication date: August 7, 2003
    Applicant: Merck Patent GmbH
    Inventor: Yukitaka Watanabe
  • STN liquid crystal display
    Publication number: 20030148043
    Abstract: The invention relates to supertwist liquid-crystal displays (SLCDs) having very short response times and good steepnesses and angular dependences and to the novel nematic liquid-crystal mixtures employed therein, which are distinguished by the fact that they comprise at least one compound of the formula IA 1
    Type: Application
    Filed: December 23, 2002
    Publication date: August 7, 2003
    Applicant: Merck Patent GmbH
    Inventor: Harald Hirschmann
  • Pearlescent pigments
    Publication number: 20030147820
    Abstract: The present invention relates to pearlescent pigments based on substrates coated with one or more layers of nitrides or oxynitrides to a method for the production of such pigments and their use in plastics, paints, coatings, powder coatings, inks, printing inks, glasses, ceramic products, agriculture foils, for lasermarking of papers and plastics, security applications and in cosmetic formulations.
    Type: Application
    Filed: January 31, 2003
    Publication date: August 7, 2003
    Applicant: MERCK PAPTENTGESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Stephane Bertaux, Peter Reynders, Jens-Uwe Wichmann, Eberhard Schweda
  • Process for purifying human papillomavirus virus-like particles
    Patent number: 6602697
    Abstract: A process for purifying papillomavirus virus-like particles (VLPs) includes the step of passing a partially purified VLP-containing solution through a hydroxyapatite chromatography column. The VLPs are then eluted using a buffer containing phosphate anion. The advantages of this method include the recovery of a high yield of intact VLPs.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventor: James C. Cook, III
  • Adhesion receptor antagonists
    Patent number: 6602876
    Abstract: Compounds of the formula I wherein R1, R2 and R3 have the meanings defined herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, ischaemias, inflammations, arteriosclerosis and osteolytic disorders.
    Type: Grant
    Filed: November 2, 1995
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer, Matthias Wiesner, Claus Fittschen
  • Transparent medium with angular-selective transmitting or reflecting properties
    Patent number: 6602340
    Abstract: The invention relates to a transparent medium comprising pearl lustre pigments having angle-selective reflection and/or transmission properties and to the use thereof, especially in transparent thermal insulation systems (TIMs).
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Christina Schank, Gerhard Pfaff, Alexandra Brownfield, Joachim Weitzel, Wolfgang Hechler
  • Electro-optical liquid-crystal display
    Patent number: 6602562
    Abstract: The invention generally relates to an electro-optical liquid-crystal display having a re-alignment layer, for re-aligning the liquid crystals, whose field has a component parallel to the liquid-crystal layer which is desirable for the re-alignment, including a liquid-crystalline medium of positive dielectric anisotropy, where the medium can include one or more compounds of the formula I and one or more compounds selected from the group of compounds of the formulae II and III in which R1, R2 and R3 are each, independent of one another, alkyl or alkoxy having 1 to 7 carbon atoms or alkenyl, alkenyloxy or alkoxyalkyl having 2 to 7 carbon atoms, Y11, Y12, Y21, Y22, Y31 and Y32 are each, independent of one another, H or F, are each, independent of one another,  and Q—X is F, Cl, —OCF2H or —OCF3.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: August 5, 2003
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Shinji Nakajima, Hideo Ichinose, Akiko Takashima, Yasushi Sugiyama
  • Polyesters containing (meth)acrylate end groups
    Patent number: 6602963
    Abstract: The invention describes polyesters containing (meth)acrylate end groups, of the general formula (I) CH2═CRCOO—PE—OCOCR═CH2 where R=CH3 or H, where PE=[—A—OCO—B—COO—]m—A—, [—CHR′—COO—]n—A—[—OCOCHR′—]n, or combinations thereof, in which A is an alkylidene radical having 2-20 carbon atoms or an alkoxylidene radical having 2-1000, preferably 2-500, alkoxylidene units, B is a saturated alkylidene radical having 2-10 carbon atoms, R′ is H or CH3, m is 1-100, n is 1-100, and, if both m and n are present, the sum m+n is 2-200, where the polyesters containing (meth)acrylate end groups are characterized in that a) the content of short-chain di(meth)acrylates (II) CH2═CRCOO—A—OCOCR═CH2 is <5% by weight, b) the content of hydroxyl groups is <0.25 mol/mol of (meth)acrylate, and c) the APHA color number is <200.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Werner Siol, Peter Pokinskyj
  • Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids
    Patent number: 6603013
    Abstract: The present invention relates to a process wherein heterogeneous finely-dispersed palladium catalysts are used in a cross-coupling reaction of alkenyl halides and aryl or heteroaryl boronic acids in the presence of base in an aprotic solvent to produce aryl- or heteroaryl-olefin compounds of Formula I:
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Yongkui Sun, Carl LeBlond, John R. Sowa, Jr.
  • Use of ectoine or ectoine derivatives in cosmetic formulations
    Patent number: 6602514
    Abstract: The use of one or more compounds chosen from the compounds of the formulae Ia and Ib the physiologically compatible salts of the compounds of the formulae Ia and Ib and the stereoisomeric forms of the compounds of the formulae Ia and Ib, where R1, R2, R3, R4 and n have the meanings given in claim 1, for the preparation of a cosmetic formulation is advantageously suitable, e.g., for protecting cells, proteins and/or biomembranes of the human skin, for protecting the microflora of the human skin, and/or for stabilizing the skin barrier.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Joachim Bünger, Hans-Jürgen Driller, Roland Martin
  • Substituted pyridazines having cytokine inhibitory activity
    Patent number: 6602872
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Charles J. McIntyre, Nigel J. Liverton, David A. Claremon
  • Apparatus and method for processing phone-in prescriptions
    Publication number: 20030144876
    Abstract: An apparatus and method are disclosed for processing phone-in prescription requests. The apparatus is in the form of a prescription processing network that includes a prescription processing system and a communication device remotely located from the prescription processing system. The communication device is used to establish a communication channel with the prescription processing system and submit a prescription request over the communication channel. A pharmacist, associated with the prescription processing system, prepares a completed prescription form based, at least in part, on the submitted prescription request. The prescription processing network also includes a pharmacy for receiving the completed prescription form, and filling the prescription request based on the completed prescription form.
    Type: Application
    Filed: January 28, 2002
    Publication date: July 31, 2003
    Applicant: Merck-Medco Managed Care, LLC
    Inventors: Diana L. Kosinski, Mark W. Sullivan, Steven M. McNamara, Melissa Russo
  • Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
    Publication number: 20030144327
    Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: 1
    Type: Application
    Filed: January 14, 2003
    Publication date: July 31, 2003
    Applicant: Merck & Co., Inc.
    Inventor: Louis S. Crocker
  • Growth hormone secretagogue related receptors and nucleic acids
    Patent number: 6599718
    Abstract: This invention relates to a new family of receptors, growth hormone secretagogue-related receptors, which exhibit moderate sequence identity to both the growth hormone secretagogue receptor (GHS-R) and the neurotensin receptor (NT-R). These newly identified receptors are expressed in a diverse set of tissues. This invention also relates to nucleic acids encoding these receptors, and to the use of these receptors to identify ligands that modulate growth hormone release as well as other modulators of endocrine function.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Qingyun Liu, Andrew D. Howard, Karen Kulju McKee
  • Process for the synthesis of (2R, 2-alpha-R, 3A)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1, 4-oxazine
    Patent number: 6600040
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Karel M. Jos Brands, Fuh-Rong Tsay, Karen M. Conrad, Matthew M. Zhao
  • Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfony)phenyl]ethanone
    Patent number: 6600046
    Abstract: The process for preparing 1-(6-methylpyridin-3-yl)-2-[(4-methlsulfonyl)-phenyl]ethanone of the formula I: In a first step, 4-(methylthio)phenylacetonitrile is condensed with a 6-methylnicotinic ester to give 3-[2-(4-(methlthio)phenyl)-2-cyanoacetyl](6-methyl)pyridine of the formula II: In a second step, the compound of formula II is hydrolyzed and decarboxylated under acidic conditions using a mixture of acetic acid and a mineral acid, to give 3-[2-(4-(methylthio)phenyl)acetyl](6-methyl)pyridine of the formula III: Finally, in a last step, the compound of formula III is oxidized to give the end product.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: July 29, 2003
    Assignees: Merck & Co., Inc., Lonza AG
    Inventors: Yves Bessard, James Edward Leresche
  • Film
    Patent number: 6599443
    Abstract: The invention relates to an optical retardation film comprising a layer of an anisotropic polymer material with an optical axis substantially parallel to the plane of the layer. The invention furthermore relates to a process of preparing the optical retardation film, to the use of such an optical retardation film in liquid crystal displays, and to a liquid crystal display device comprising a liquid crystal cell and such an optical retardation film.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: July 29, 2003
    Assignees: Rockwell Technologies, LLC, Merck Patent GmbH
    Inventors: Nicholas Sharples, Gabrielle Egan, Young Chung, Zhiming Zhuang, Zili Li, Bruce K. Winker, Jane H. Hanamoto, David Coates
  • Method of establishing synthesis paths
    Patent number: 6600970
    Abstract: A method of establishing a synthesis path in a multiplicity of potentially interlinakable reactions, and a computer program to prepare a synthesis path.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck Patent GmbH
    Inventor: Klemens Bley